fda approved weight loss glp-1 Approves First Generic Liraglutide for FDA approves Foundayo, an oral

The program is designed for individuals who are taking weight-loss medications and would like support in developing sustainable healthy habits for long-term weight management

Dr Jastreboff notes that mild to moderate gastrointestinal side effects are possible

The data shows that discontinuing GLP-1 medications leads to significant weight regain in the majority of patients

A metabolism that slows instead of strengthens

As well as physical health risks, the stigma attached to excess body weight and obesity can have adverse psychosocial consequences and lower the quality of life

This interaction is widely documented but frequently overlooked in clinical practice